sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Dimenhydrinate may decrease emetic response to apomorphine.
|
Dimenhydrinate
|
apomorphine
|
EFFECT
|
Dimenhydrinate_ddi.xml
|
DDI-DrugBank.d96.s0
|
DDI-DrugBank.d96.s0.p1
|
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
sulfonamides
|
EFFECT
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s0
|
DDI-DrugBank.d178.s0.p2
|
Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
|
sulfasalazine
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s6
|
DDI-DrugBank.d450.s6.p14
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
dextran
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p13
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylurea
|
probenecid
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p4
|
Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
|
Epinephrine
|
sympathomimetic drugs
|
ADVISE
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s2
|
DDI-DrugBank.d247.s2.p0
|
Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
|
quinolones
|
Videx
|
MECHANISM
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s7
|
DDI-DrugBank.d562.s7.p3
|
Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
|
acetazolamide
|
amphetamine
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s5
|
DDI-DrugBank.d236.s5.p1
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
glutethimide
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p12
|
After multiple dosing, interferon beta-1a (AVONEX 30 mcg IM once weekly) reduced TYSABRI clearance by approximately 30%.
|
interferon beta-1a
|
TYSABRI
|
MECHANISM
|
Natalizumab_ddi.xml
|
DDI-DrugBank.d232.s0
|
DDI-DrugBank.d232.s0.p1
|
Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45 (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
|
D.H.E. 45
|
propranolol
|
NONE
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s3
|
DDI-DrugBank.d410.s3.p6
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
alprazolam
|
ergotamine
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p6
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
corticotropin
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p6
|
Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
|
nitrous oxide
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s6
|
DDI-DrugBank.d60.s6.p11
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Stelazine
|
trimeprazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p292
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
polymyxins
|
procainamide
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p67
|
Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.
|
chloroprocaine
|
sulfonamide drug
|
ADVISE
|
Chloroprocaine_ddi.xml
|
DDI-DrugBank.d110.s5
|
DDI-DrugBank.d110.s5.p0
|
Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
|
Anti-arrhythmics
|
bepridil hydrochloride
|
EFFECT
|
Bepridil_ddi.xml
|
DDI-DrugBank.d137.s10
|
DDI-DrugBank.d137.s10.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
prolonged narcotics
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p39
|
Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
|
PRINIVIL
|
amiloride
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s15
|
DDI-DrugBank.d334.s15.p3
|
Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
|
caffeine
|
cimetidine
|
ADVISE
|
Caffeine_ddi.xml
|
DDI-DrugBank.d89.s3
|
DDI-DrugBank.d89.s3.p1
|
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
|
dapsone
|
glutethimide
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s13
|
DDI-DrugBank.d263.s13.p44
|
The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.
|
EMTRIVA
|
tenofovir disoproxil fumarate
|
NONE
|
Emtricitabine_ddi.xml
|
DDI-DrugBank.d375.s0
|
DDI-DrugBank.d375.s0.p3
|
conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
|
diethylpropion
|
antihypertensive drugs
|
INT
|
Diethylpropion_ddi.xml
|
DDI-DrugBank.d352.s3
|
DDI-DrugBank.d352.s3.p0
|
Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
|
Indinavir
|
indinavir
|
NONE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s14
|
DDI-DrugBank.d340.s14.p0
|
In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
|
methylxanthines
|
adenosine
|
ADVISE
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s5
|
DDI-DrugBank.d226.s5.p0
|
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.
|
penicillins
|
probenecid
|
MECHANISM
|
15830476.xml
|
DDI-MedLine.d29.s2
|
DDI-MedLine.d29.s2.p1
|
Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.
|
INDOCIN
|
anticoagulants
|
ADVISE
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s8
|
DDI-DrugBank.d82.s8.p0
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
anesthetics
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p4
|
Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
|
sucralfate
|
quinolones
|
MECHANISM
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s6
|
DDI-DrugBank.d562.s6.p2
|
When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.
|
probenecid
|
ertapenem
|
MECHANISM
|
Ertapenem_ddi.xml
|
DDI-DrugBank.d329.s0
|
DDI-DrugBank.d329.s0.p5
|
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
|
penicillin
|
tetracyclines
|
NONE
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s1
|
DDI-DrugBank.d500.s1.p0
|
The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.
|
INDOCIN
|
potassium-sparing diuretics
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s31
|
DDI-DrugBank.d82.s31.p0
|
Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).
|
propranolol
|
atenolol
|
NONE
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s7
|
DDI-DrugBank.d529.s7.p5
|
Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
|
clozapine
|
benzodiazepine
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s8
|
DDI-DrugBank.d480.s8.p12
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
Benzthiazide
|
NSAIDs
|
INT
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p5
|
EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
|
EDECRIN
|
aminoglycoside
|
EFFECT
|
Ethacrynic acid_ddi.xml
|
DDI-DrugBank.d414.s2
|
DDI-DrugBank.d414.s2.p0
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
Benzthiazide
|
norepinephrine
|
INT
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p4
|
Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
|
Benazepril
|
beta-adrenergic blockers
|
EFFECT
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s12
|
DDI-DrugBank.d561.s12.p1
|
however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.
|
aspirin
|
ketoprofen
|
MECHANISM
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s6
|
DDI-DrugBank.d499.s6.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
desipramine
|
Phenytoin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p493
|
Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
|
PRINIVIL
|
potassium
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s15
|
DDI-DrugBank.d334.s15.p4
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
fluoxetine
|
sulfonamides
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p173
|
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
|
simvastatin
|
clarithromycin
|
EFFECT
|
11197581.xml
|
DDI-MedLine.d25.s0
|
DDI-MedLine.d25.s0.p0
|
Effects of Other Antiepileptic Drugs on Felbatol Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.
|
phenytoin
|
Felbatol
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s30
|
DDI-DrugBank.d434.s30.p33
|
Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
|
corticosteroid
|
live vaccines
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s30
|
DDI-DrugBank.d314.s30.p3
|
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
|
steroidal anti-inflammatory agent
|
loop diuretics
|
EFFECT
|
Hydroflumethiazide_ddi.xml
|
DDI-DrugBank.d17.s25
|
DDI-DrugBank.d17.s25.p0
|
In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
|
heparin
|
thrombolytics
|
NONE
|
Bivalirudin_ddi.xml
|
DDI-DrugBank.d569.s1
|
DDI-DrugBank.d569.s1.p4
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
pertechnetate
|
phenobarbital
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p202
|
FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
|
FLEXERIL
|
barbiturates
|
EFFECT
|
Cyclobenzaprine_ddi.xml
|
DDI-DrugBank.d150.s1
|
DDI-DrugBank.d150.s1.p1
|
Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
|
aluminum hydroxide
|
enoxacin
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s17
|
DDI-DrugBank.d395.s17.p4
|
Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
|
Probenecid
|
ampicillin
|
MECHANISM
|
Ampicillin_ddi.xml
|
DDI-DrugBank.d211.s5
|
DDI-DrugBank.d211.s5.p0
|
Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
|
epinephrine
|
cyclopropane
|
EFFECT
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s5
|
DDI-DrugBank.d247.s5.p0
|
Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
|
Erythromycin
|
benzodiazepines
|
EFFECT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s6
|
DDI-DrugBank.d397.s6.p2
|
Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.
|
ROMAZICON
|
benzodiazepine
|
EFFECT
|
Flumazenil_ddi.xml
|
DDI-DrugBank.d234.s4
|
DDI-DrugBank.d234.s4.p0
|
Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.
|
Urinary acidifying
|
amphetamines
|
MECHANISM
|
Benzphetamine_ddi.xml
|
DDI-DrugBank.d477.s5
|
DDI-DrugBank.d477.s5.p0
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
furosemide
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p6
|
Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.
|
Trileptal
|
phenytoin
|
ADVISE
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s36
|
DDI-DrugBank.d307.s36.p0
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
anticholinergic
|
narcotic analgesics
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p1
|
Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
|
Tetracycline
|
penicillin
|
EFFECT
|
Nafcillin_ddi.xml
|
DDI-DrugBank.d261.s0
|
DDI-DrugBank.d261.s0.p1
|
However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
|
NSAIDs
|
Ibandronate
|
ADVISE
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s13
|
DDI-DrugBank.d440.s13.p14
|
Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
|
digoxin
|
antithyroid agents
|
MECHANISM
|
Carbimazole_ddi.xml
|
DDI-DrugBank.d213.s1
|
DDI-DrugBank.d213.s1.p1
|
Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.
|
iloprost
|
anticoagulants
|
EFFECT
|
Iloprost_ddi.xml
|
DDI-DrugBank.d549.s2
|
DDI-DrugBank.d549.s2.p0
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
metoprolol
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p12
|
Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
|
hormonal contraceptives
|
diazepam
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s17
|
DDI-DrugBank.d485.s17.p11
|
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
|
antacids
|
ranitidine
|
NONE
|
Diatrizoate_ddi.xml
|
DDI-DrugBank.d293.s0
|
DDI-DrugBank.d293.s0.p17
|
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
|
TORADOL
|
psychoactive drugs
|
EFFECT
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s19
|
DDI-DrugBank.d3.s19.p5
|
Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
|
agents with b-blocking properties
|
reserpine
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s3
|
DDI-DrugBank.d269.s3.p0
|
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
|
benzodiazepines
|
isoniazide
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s8
|
DDI-DrugBank.d338.s8.p4
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
procainamide
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p27
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
anticonvulsants
|
temazepam
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p283
|
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
|
Lodine
|
digoxin
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s7
|
DDI-DrugBank.d219.s7.p2
|
Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
|
Erythromycin
|
triazolam
|
EFFECT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s19
|
DDI-DrugBank.d522.s19.p4
|
Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.
|
carbamazepine
|
lapatinib
|
MECHANISM
|
Lapatinib_ddi.xml
|
DDI-DrugBank.d135.s8
|
DDI-DrugBank.d135.s8.p2
|
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
|
non-steroidal anti-inflammatory agent
|
thiazide diuretics
|
EFFECT
|
Amiloride_ddi.xml
|
DDI-DrugBank.d356.s4
|
DDI-DrugBank.d356.s4.p2
|
MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
|
furazolidone
|
amphetamine
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s6
|
DDI-DrugBank.d158.s6.p5
|
Warfarin: Meclofenamate sodium enhances the effect of warfarin.
|
Warfarin
|
Meclofenamate sodium
|
EFFECT
|
Meclofenamic acid_ddi.xml
|
DDI-DrugBank.d113.s0
|
DDI-DrugBank.d113.s0.p0
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
iron
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p5
|
Compounds that have been tested in man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.
|
digoxin
|
warfarin
|
NONE
|
Finasteride_ddi.xml
|
DDI-DrugBank.d209.s2
|
DDI-DrugBank.d209.s2.p6
|
Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.
|
L-arginine
|
sildenafil citrate
|
EFFECT
|
L-Arginine_ddi.xml
|
DDI-DrugBank.d95.s3
|
DDI-DrugBank.d95.s3.p2
|
There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
|
furosemide
|
NSAIDs
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s14
|
DDI-DrugBank.d231.s14.p0
|
Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.
|
Medroxyprogesterone Acetate
|
medroxyprogesterone acetate
|
NONE
|
L-Histidine_ddi.xml
|
DDI-DrugBank.d365.s0
|
DDI-DrugBank.d365.s0.p1
|
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
|
Diuretic agents
|
lithium
|
MECHANISM
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s16
|
DDI-DrugBank.d46.s16.p1
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
quinidine
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p28
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
|
diuretics
|
nicotinic acid
|
NONE
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s1
|
DDI-DrugBank.d536.s1.p17
|
Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
|
Ketoprofen
|
methotrexate
|
MECHANISM
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s22
|
DDI-DrugBank.d499.s22.p4
|
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
|
nitric oxide donor compounds
|
nitroglycerin
|
NONE
|
Nitric Oxide_ddi.xml
|
DDI-DrugBank.d183.s2
|
DDI-DrugBank.d183.s2.p1
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
opioids
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p24
|
During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).
|
amiodarone
|
digoxin
|
MECHANISM
|
3964797.xml
|
DDI-MedLine.d61.s4
|
DDI-MedLine.d61.s4.p0
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
Advil
|
Anaprox
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p107
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
delavirdine
|
ketoconazole
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p167
|
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
|
estazolam
|
estazolam
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s4
|
DDI-DrugBank.d338.s4.p4
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Prelone
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p37
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
erythromycin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p8
|
Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
|
WELLBUTRIN
|
antidepressants
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s22
|
DDI-DrugBank.d5.s22.p1
|
Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
|
Argatroban
|
thrombolytics
|
EFFECT
|
Argatroban_ddi.xml
|
DDI-DrugBank.d148.s6
|
DDI-DrugBank.d148.s6.p1
|
Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
|
Bosentan
|
statins
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s27
|
DDI-DrugBank.d289.s27.p0
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
chlorpromazine
|
trihexyphenidyl
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p6
|
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.
|
phenelzine sulfate
|
MAO inhibitors
|
NONE
|
L-Tyrosine_ddi.xml
|
DDI-DrugBank.d111.s0
|
DDI-DrugBank.d111.s0.p11
|
Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
|
cisapride
|
ketoconazole
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s7
|
DDI-DrugBank.d76.s7.p5
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.